Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00032032 · ClinicalTrials.gov registry record · Phase 1
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer
A Phase 1 study of Lung Cancer, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 69
- Enrollment target
- 20
- Study locations
NCT00032032: Completed Phase 1 study of Lung Cancer, sponsored by Alliance for Clinical Trials in Oncology.
NCT00032032 is a Phase 1 study of Lung Cancer that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 69 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00032032, a Phase 1 study of Lung Cancer, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 69 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy and radiation therapy may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of radiation therapy when given with combination chemotherapy and to see how well they work in treating patients with non-small cell lung cancer that cannot be surgically removed.
Conditions Studied
Interventions
- DRUG carboplatin
- DRUG paclitaxel
- RADIATION radiation therapy
Study Locations (20)
Iowa
- McFarland Clinic, PC - Ames
- Mercy Capitol Hospital - Des Moines
- CCOP - Iowa Oncology Research Association - Des Moines
- John Stoddard Cancer Center at Iowa Methodist Medical Center - Des Moines
- Medical Oncology and Hematology Associates at John Stoddard Cancer Center - Des Moines
- Medical Oncology and Hematology Associates at Mercy Cancer Center - Des Moines
- Mercy Cancer Center at Mercy Medical Center - Des Moines - Des Moines
- John Stoddard Cancer Center at Iowa Lutheran Hospital - Des Moines
- Siouxland Hematology-Oncology Associates, LLP - Sioux City
- Mercy Medical Center - Sioux City - Sioux City
- St. Luke's Regional Medical Center - Sioux City
Michigan
- Hickman Cancer Center at Bixby Medical Center - Adrian
- Haematology-Oncology Associates of Ohio and Michigan, PC - Lambertville
- Community Cancer Center of Monroe - Monroe
- Mercy Memorial Hospital - Monroe - Monroe
Minnesota
- MeritCare Bemidji - Bemidji
- Mayo Clinic Cancer Center - Rochester
Arizona
- Mayo Clinic Scottsdale - Scottsdale
Florida
- Mayo Clinic - Jacksonville - Jacksonville
Nebraska
- CCOP - Missouri Valley Cancer Consortium - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2002-05 |
| Est. Completion | 2010-01 |
| Phase | Phase 1 |
What the finished NCT00032032 record still lists
NCT00032032 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 69 participants, a relatively small participant target, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which carboplatin is the first listed.
NCT00032032 names 20 study sites across 6 states, led by Iowa, Michigan, Minnesota.
Frequently Asked Questions
What is clinical trial NCT00032032 about?
NCT00032032 is a clinical study titled "Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy and radiation therapy may kill more tumor cells. PURPOSE: This phase I/II trial is studying...
What is the current status of trial NCT00032032?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 69 participants. The study started on 2002-05. Estimated completion is 2010-01.
What conditions does trial NCT00032032 study?
This clinical trial studies the following conditions: Lung Cancer.
What interventions are being tested in trial NCT00032032?
The interventions under investigation include: carboplatin (DRUG), paclitaxel (DRUG), radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT00032032?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00032032 being conducted?
This trial has 20 study locations across Arizona, Florida, Iowa, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00032032's enrollment target sits among peer trials
69 229th of 409 higher than 180 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04020575 · 69 participants · Phase 1
Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
- NCT04163614 · 69 participants · NA
Blood Pressure Slopes and Ultrafiltration in Hemodialysis Patients
- NCT04164641 · 69 participants · NA
Noraxon myoRESEARCH™ Software Gait Analysis Evaluation and Orthotic Gait Correction in Reducing Diabetic Foot Ulceration Or Subsequent Amputation in Patients With a History of a Diabetic Foot Ulceration
- NCT04493372 · 69 participants · NA
Deciphering Preserved Autonomic Function After Spinal Cord Injury
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia